View Cart  

Warning to Costa Rican Hospira Plant Hints at Bigger Problems, Analysts Say

A A
An FDA warning letter issued to Hospira’s infusion pump plant in Costa Rica may be emblematic of broader companywide manufacturing issues, analysts say.

To View This Article:

Login

Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00